All In MedTech

Device Trial Radar · NCT03831919

Trial of Hoya SYNC III Design Lenses

Randomised Controlled Trial of Hoya SYNC III Design Lenses

Last checked: Nov 20, 2026Latest source record: Jul 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Jan 7, 2019

Primary completion

Jun 30, 2020

Study completion Jun 30, 2020

Sponsor

Lead sponsor
The Institute of Optometry, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Alicante
First posted
Feb 6, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Many people using computers or digital devices (e.g., smartphones or tablets) experience eyestrain and this has been called Computer Vision Syndrome (CVS) or Digital Eye Strain. Spectacle lens manufacturers have designed products to alleviate the symptoms of CVS. One such product, designed by Hoya (SYNC III), aims to do this by providing accommodative support. The present study is a parallel group double-masked RCT of people with CVS. One group will receive Hoya SYNC III lenses and the other (control) group single vision (SV) lenses. The main aims are to evaluate whether: 1. binocular vision and accommodative functions at baseline can predict participants who benefit from SYNC III design lenses; 2. the wearing of SYNC III design lenses is associated with any changes in binocular and accommodative functions at 6 months of follow-up; 3. the wearing of lenses with accommodative support reduce the symptoms of computer vision syndrome at 3 and 6 months of follow-up. Participants will be examined three times: at baseline and three and six months after receiving their lenses. The group who receive control lenses will be provided with SYNC III lenses at the end of the six month trial for a brief one week follow-up evaluation.

Conditions

  • Computer Vision Syndrome

Interventions

  • SYNC IIIDevice

    Hoya SYNC III design spectacle lenses

  • single vision lensesDevice

    single vision spectacle lenses with no addition

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in CVS-QTime frame: Baseline, three-month follow-up, six-month follow-up
  2. Change in heterophoriaTime frame: Baseline, three-month follow-up, six-month follow-up
  3. Change in aligning prismTime frame: Baseline, three-month follow-up, six-month follow-up

4 more outcomes with a free account

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alicante

    Alicante, Spain

  • Institute of Optometry

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.